UBS Points to Two Top European Luxury Stocks Ahead of 2026 Upswing
DUBLIN - Bank of America Corporation has disclosed a 3.006% interest in Avadel Pharmaceuticals plc, according to a regulatory filing released today.
The disclosure, made under the Irish Takeover Panel rules, reveals that Bank of America holds 2,927,979 shares in the pharmaceutical company as of November 25, 2025. This position includes 2,787,024 owned or controlled relevant securities and 140,955 cash-settled derivatives.
The filing also shows Bank of America maintains short positions totaling 1.929% of Avadel’s shares, consisting of 1,016,986 relevant securities and 861,518 cash-settled derivatives.
The disclosure details several transactions conducted on November 25, including purchases of Avadel common shares at prices ranging from $22.88 to $22.97 per share. The largest single purchase involved 76,419 shares at $22.93.
Multiple sales transactions were also reported, with prices ranging from $22.88 to $23.00 per share. Additionally, Bank of America closed a long position of 70,000 shares through swaps at $22.93 per share.
The filing was submitted in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires persons with interests in relevant securities representing 1% or more to disclose their positions.
Avadel Pharmaceuticals, headquartered in Ireland, is listed on the Nasdaq exchange. The disclosure indicates Bank of America is not making disclosures regarding any other party to a potential offer.
This information is based on a regulatory filing statement submitted to the Irish Takeover Panel.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.